Endocrine therapy is the most effective treatment option for estrogen-receptor (ER) positive breast cancer, but its efficacy is limited by both intrinsic and acquired endocrine resistance. Roughly a quarter of patients with primary tumors and nearly all patients with metastases will eventually develop endocrine resistance. While the mechanism of endocrine resistance remains poorly understood, emerging evidence suggests that mutations or fusions of the ESR1 gene are important driving mechanisms.
Li, L., Lin, L., Veeraraghavan, J., Hu, Y., Wang, X., Lee, S., Tan, Y., Schiff, R., & Wang, X.-S. (2020). Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2020.06.26.149948